Disclosures

As organizations accredited by the ACCME, the Medical College of Wisconsin and Medscape, LLC, require everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

• Camille Nelson Kotton, MD

  Clinical Director
  Transplant and Immunocompromised Host Infectious Diseases
  Massachusetts General Hospital
  Boston, Massachusetts

  Disclosure: Camille Nelson Kotton, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Hookipa; Merck; Roche Diagnostics; Takeda
  Served as a speaker or a member of a speakers bureau for: Roche Diagnostics

• Francisco M. Marty, MD

  Associate Professor of Medicine
  Harvard Medical School
  Associate Physician
  Brigham and Women's Hospital
  Boston, Massachusetts

  Disclosure: Francisco M. Marty, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: AlloVir; Amplyx; Avir; F2G; Gilead; Janssen; Kyorin; Merck; Regeneron; ReViral; Symbio; United Medical
  Received grants for clinical research from: Amplyx; Ansun; Chimerix; Cidara; F2G; Gilead; Merck; Regeneron; Scynexis; Takeda; WHISCON

• Genovefa Papanicolaou, MD

  Director
  Clinical Trials
  Infectious Disease Service
  Memorial Sloan Kettering Cancer Center
  Weill Cornell Medicine
  New York, New York

  Disclosure: Genovefa A. Papanicolaou, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: ADMA Biologics; Astellas; Cidara; Merck; Octapharma; Partner Therapeutics; Siemens; Shionogi
  Received grants for clinical research from: Astellas; Merck & Co.; Takeda
  Other: Allovir; Amplyz; DSMC; EAC Octapharma

Editor

• Maria B. Uravich, BSc, ELS

  Senior Medical Education Director, Medscape, LLC

  Disclosure: Maria B. Uravich, BSc, ELS, has disclosed no relevant financial relationships.

CME, CE Reviewer/Nurse Planner

• Stephanie Corder, ND, RN, CHCP

  Associate Director, Accreditation and Compliance, Medscape, LLC

  Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Reviewer

• Bronwen E. Shaw, MD, PhD

  Disclosure: Bronwen E. Shaw, MD, PhD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Orca bio; Therakos
  Received honorarium from: Therakos
  Additional Disclosure: CIBMTR receives financial support from the government, foundations and industry entities listed below to support broad research and educational missions. These funding sources are disclosed for transparency. Scientific and administrative review processes prevent direct influence of the funding sources to the CIBMTR scientific research agenda and individual research products and findings.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc., and Merk & co., Inc.